Clinical Trial Update: Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab vedotin in advanced systemic mastocytosis or mast cell leukemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Jason Robert Gotlib | Conditions: Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-01-29